Summary
Stryker Corporation's 2016 Form 10-K highlights a strong year of growth, with net sales increasing by 13.9% to $11.3 billion, driven by robust performance across its business segments, particularly MedSurg and Neurotechnology and Spine. The company successfully executed its strategic capital allocation, investing significantly in acquisitions, notably Sage Products and Physio-Control, which are expected to bolster its offerings in intensive care disposable products and emergency medical equipment, respectively. While reporting net earnings of $1.65 billion, an increase from the previous year, investors should note the impact of recall charges related to the Rejuvenate and ABG II hip stems, which continue to affect the company's financial results, though at a reduced level compared to prior years. The company also demonstrated a commitment to shareholder returns through dividend payments. Looking ahead, Stryker is well-positioned with a diversified product portfolio and a continued focus on innovation, as evidenced by its consistent investment in research and development. The company faces a competitive landscape and regulatory scrutiny, common in the medical technology sector, but its strong financial position, including significant cash and credit facilities, provides a solid foundation for future growth and its strategic objectives, including further acquisitions and organic expansion. Investors should monitor the ongoing resolution of product liability matters and the company's ability to integrate recent acquisitions successfully.
Financial Highlights
55 data points| Revenue | $11.32B |
| Cost of Revenue | $3.83B |
| Gross Profit | $7.50B |
| R&D Expenses | $715.00M |
| SG&A Expenses | $4.14B |
| Operating Expenses | $5.33B |
| Operating Income | $2.17B |
| Interest Expense | $228.00M |
| Net Income | $1.65B |
| EPS (Basic) | $4.40 |
| EPS (Diluted) | $4.35 |
| Shares Outstanding (Basic) | 374.10M |
| Shares Outstanding (Diluted) | 378.50M |
Key Highlights
- 1Stryker reported a 13.9% increase in net sales for 2016, reaching $11.3 billion, indicating strong top-line growth.
- 2The company made significant strategic acquisitions in 2016, including Sage Products ($2.875 billion) and Physio-Control ($1.299 billion), expanding its product portfolio in key growth areas.
- 3Net earnings grew to $1.647 billion in 2016, a 14.5% increase from 2015, demonstrating improved profitability.
- 4The MedSurg segment experienced substantial growth (25.6% increase in net sales), largely driven by acquisitions and strong performance in Instruments, Endoscopy, and Medical product lines.
- 5Recall charges related to the Rejuvenate and ABG II hip stems decreased significantly to $158 million in 2016 from $296 million in 2015, signaling progress in resolving these legacy issues.
- 6The company maintained a strong balance sheet, with total assets growing to $20.4 billion and shareholders' equity at $9.55 billion, supported by consistent operating cash flow.
- 7Stryker continued its capital allocation strategy, investing $4.33 billion in acquisitions, paying $568 million in dividends, and repurchasing shares.